ArticleEuropean journal of pediatrics2025
Prognostic factors and treatment outcomes of hepatoblastoma in children: a SEER database analysis.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies.Cancers · 2026Review
- Treatment and outcomes of hepatoblastoma in a tertiary care pediatric institution: a single-center experience.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatoblastoma (HB) is the most common primary liver malignancy in children. This study aimed to construct a clinical prediction model to quantitatively assess the overall survival (OS) and cancer-specific survival (CSS) of pediatric patients with HB and to analyze the impact of different treatment methods on prognosis. HB patients' clinical characteristics and treatment data were extracted from the SEER database. Prognostic variables were selected using univariate and multivariate Cox proportional hazards regression analyses, and a survival prediction model was subsequently constructed. The performance of the nomogram was evaluated using the concordance index (C-index), calibration plots, and receiver operating characteristic (ROC) curves. The prognostic impact of different treatment modalities was further assessed through Kaplan-Meier analysis and subgroup analyses. A total of 424 HB patients were included. Univariate Cox regression analysis and multivariate Cox regression analysis identified several independent prognostic factors, including race, surgical intervention, and tumor metastasis, as independent prognostic factors for OS. In contrast, race, surgical intervention, distant metastasis, and chemotherapy were independent predictors for CSS. All AUC values substantially exceeded the 0.7 threshold for satisfactory predictive capacity. Calibration plots revealed close agreement between predicted and observed survival probabilities. Subgroup analysis further revealed that younger patients exhibited significantly better prognoses when treated with chemotherapy, underscoring its critical role in survival outcomes. Conclusion: The study successfully established a clinical prediction model for HB, enabling quantification of the impact of clinical characteristics on OS and CSS, as well as individualized survival prediction and risk stratification. Subgroup analyses highlighting prognostic variations among treatment strategies provide an evidence-based foundation for optimizing therapeutic approaches in pediatric HB patients. What is Known? • Hepatoblastoma (HB) is the most common primary liver malignancy in children. What is New? • A clinical prediction model was constructed to quantitatively assess the overall survival (OS) and cancer-specific survival (CSS) of pediatric patients with HB.
Indexed as
Identifiers
41060454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.